Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anus Neoplasms 2Rectal Neoplasms 1HIV Infections 1Anal Canal Carcinoma 1

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Etoposide 2Cyclophosphamide 2liposomal doxorubicin 1fludarabine 1dehydroftorafur 1carmustine, poliferprosan 20 drug combination 1cabozantinib 1axicabtagene ciloleucel 1Zidovudine 1Vincristine 1Valganciclovir 1Standard of Care 1Smoking Devices 1Sirolimus 1Sigmoidoscopy 1Sentinel Lymph Node Biopsy 1Rituximab 1Raltegravir Potassium 1Radiotherapy, Intensity-Modulated 1Proctoscopy 1Prednisone 1Practice Guidelines as Topic 1Peripheral Blood Stem Cell Transplantation 1Mitozytrex 1Mitomycin 1Melphalan 1Interferon-alpha 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HIV Infections × Proctoscopy × 90 days × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡